Comparative Evaluation of Erythropoietin therapy with and Without Iron Supplementation in Anemia Among CKD Patients on Hemodialysis

Abstract

Anemia in chronic kidney disease (CKD) represents a significant clinical challenge resulting from impaired endogenous erythropoietin (EPO) production and reduced red blood cell survival, necessitating therapeutic intervention to improve patient outcomes and quality of life. This prospective observational study evaluated the comparative efficacy and clinical impact of erythropoietin therapy administered with and without iron supplementation (intravenous or oral) in 83 CKD patients undergoing maintenance hemodialysis at Gandhi Hospital, Hyderabad, comprising 56 males (67.5%) and 27 females (32.5%), aged 20–80 years. Hypertension emerged as the predominant underlying etiology of CKD (68% of patients), followed by diabetes mellitus, with anemia prevalence increasing progressively with advancing age, reflecting the age-related decline in renal erythropoietin synthesis. Treatment pattern analysis revealed heterogeneous EPO utilization: some patients received regular erythropoietin therapy, others received irregular dosing, and 33 patients (39.8%) did not receive EPO due to socioeconomic constraints. Hemoglobin correction and clinical outcomes were substantially superior in patients receiving erythropoietin in combination with iron supplementation, particularly those receiving intravenous iron, compared to those on EPO monotherapy or irregular treatment regimens. Both oral and intravenous iron supplementation enhanced erythropoietin response; however, intravenous administration demonstrated superior efficacy in patients with advanced anemia or compromised gastrointestinal absorption. Adherence to regular erythropoietin therapy combined with appropriate iron supplementation significantly enhanced anemia management, slowed CKD disease progression, and improved patient-reported quality of life measures. Conversely, irregular treatment patterns or financial inability to access therapy were associated with persistent anemia, increased complications, and adverse clinical outcomes. These findings establish erythropoietin combined with iron supplementation as a cornerstone therapeutic strategy in anemia management for hemodialysis patients. The study underscores the critical importance of early diagnosis and aggressive management of hypertension and diabetes mellitus to mitigate CKD progression. Additionally, socioeconomic support mechanisms and patient counseling regarding medication adherence are essential to optimize treatment accessibility and clinical efficacy. Future investigations should prioritize identification of cost-effective iron supplementation strategies, evaluation of newer erythropoiesis-stimulating agents, and development of comprehensive management protocols integrating nutritional support, blood pressure control, and hematologic optimization to enhance long-term survival and quality of life in CKD patients on maintenance hemodialysis.